These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

994 related articles for article (PubMed ID: 31862477)

  • 21. The ErbB/HER family of protein-tyrosine kinases and cancer.
    Roskoski R
    Pharmacol Res; 2014 Jan; 79():34-74. PubMed ID: 24269963
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The role of small molecule platelet-derived growth factor receptor (PDGFR) inhibitors in the treatment of neoplastic disorders.
    Roskoski R
    Pharmacol Res; 2018 Mar; 129():65-83. PubMed ID: 29408302
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Role of RET protein-tyrosine kinase inhibitors in the treatment RET-driven thyroid and lung cancers.
    Roskoski R; Sadeghi-Nejad A
    Pharmacol Res; 2018 Feb; 128():1-17. PubMed ID: 29284153
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Classification of small molecule protein kinase inhibitors based upon the structures of their drug-enzyme complexes.
    Roskoski R
    Pharmacol Res; 2016 Jan; 103():26-48. PubMed ID: 26529477
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The role of small molecule Kit protein-tyrosine kinase inhibitors in the treatment of neoplastic disorders.
    Roskoski R
    Pharmacol Res; 2018 Jul; 133():35-52. PubMed ID: 29704617
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Orally effective FDA-approved protein kinase targeted covalent inhibitors (TCIs).
    Roskoski R
    Pharmacol Res; 2021 Mar; 165():105422. PubMed ID: 33434619
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Vascular endothelial growth factor (VEGF) and VEGF receptor inhibitors in the treatment of renal cell carcinomas.
    Roskoski R
    Pharmacol Res; 2017 Jun; 120():116-132. PubMed ID: 28330784
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Allosteric MEK1/2 inhibitors including cobimetanib and trametinib in the treatment of cutaneous melanomas.
    Roskoski R
    Pharmacol Res; 2017 Mar; 117():20-31. PubMed ID: 27956260
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hydrophobic and polar interactions of FDA-approved small molecule protein kinase inhibitors with their target enzymes.
    Roskoski R
    Pharmacol Res; 2021 Jul; 169():105660. PubMed ID: 33971270
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cyclin-dependent protein kinase inhibitors including palbociclib as anticancer drugs.
    Roskoski R
    Pharmacol Res; 2016 May; 107():249-275. PubMed ID: 26995305
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Src protein-tyrosine kinase structure, mechanism, and small molecule inhibitors.
    Roskoski R
    Pharmacol Res; 2015 Apr; 94():9-25. PubMed ID: 25662515
    [TBL] [Abstract][Full Text] [Related]  

  • 32. ErbB/HER protein-tyrosine kinases: Structures and small molecule inhibitors.
    Roskoski R
    Pharmacol Res; 2014 Sep; 87():42-59. PubMed ID: 24928736
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Target-Driven Tissue-Agnostic Drug Approvals-A New Path of Drug Development.
    Thein KZ; Myat YM; Park BS; Panigrahi K; Kummar S
    Cancers (Basel); 2024 Jul; 16(14):. PubMed ID: 39061168
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cyclin-dependent protein serine/threonine kinase inhibitors as anticancer drugs.
    Roskoski R
    Pharmacol Res; 2019 Jan; 139():471-488. PubMed ID: 30508677
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Therapeutic implication of vascular endothelial growth factor receptor-1 (VEGFR-1) targeting in cancer cells and tumor microenvironment by competitive and non-competitive inhibitors.
    Lacal PM; Graziani G
    Pharmacol Res; 2018 Oct; 136():97-107. PubMed ID: 30170190
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Entrectinib, a Pan-TRK, ROS1, and ALK Inhibitor with Activity in Multiple Molecularly Defined Cancer Indications.
    Ardini E; Menichincheri M; Banfi P; Bosotti R; De Ponti C; Pulci R; Ballinari D; Ciomei M; Texido G; Degrassi A; Avanzi N; Amboldi N; Saccardo MB; Casero D; Orsini P; Bandiera T; Mologni L; Anderson D; Wei G; Harris J; Vernier JM; Li G; Felder E; Donati D; Isacchi A; Pesenti E; Magnaghi P; Galvani A
    Mol Cancer Ther; 2016 Apr; 15(4):628-39. PubMed ID: 26939704
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ibrutinib inhibition of Bruton protein-tyrosine kinase (BTK) in the treatment of B cell neoplasms.
    Roskoski R
    Pharmacol Res; 2016 Nov; 113(Pt A):395-408. PubMed ID: 27641927
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Protein kinase inhibitors: contributions from structure to clinical compounds.
    Johnson LN
    Q Rev Biophys; 2009 Feb; 42(1):1-40. PubMed ID: 19296866
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Entrectinib in children and young adults with solid or primary CNS tumors harboring NTRK, ROS1, or ALK aberrations (STARTRK-NG).
    Desai AV; Robinson GW; Gauvain K; Basu EM; Macy ME; Maese L; Whipple NS; Sabnis AJ; Foster JH; Shusterman S; Yoon J; Weiss BD; Abdelbaki MS; Armstrong AE; Cash T; Pratilas CA; Corradini N; Marshall LV; Farid-Kapadia M; Chohan S; Devlin C; Meneses-Lorente G; Cardenas A; Hutchinson KE; Bergthold G; Caron H; Chow Maneval E; Gajjar A; Fox E
    Neuro Oncol; 2022 Oct; 24(10):1776-1789. PubMed ID: 35395680
    [TBL] [Abstract][Full Text] [Related]  

  • 40. ALK inhibitors in the treatment of advanced NSCLC.
    Gridelli C; Peters S; Sgambato A; Casaluce F; Adjei AA; Ciardiello F
    Cancer Treat Rev; 2014 Mar; 40(2):300-6. PubMed ID: 23931927
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 50.